News & Events

Keyword:

Practice Area:

Archive Year:

Recent Venture Capital Transactions

08 December 2011

Mason Hayes & Curran are pleased to have acted in three recent venture capital transactions which were led by Corporate Partner, Martin Kelleher and Associate, Dylan Latimer.

Genable

Mason Hayes & Curran acted for Genable Technologies Limited on a €5,000,000 investment by Fountain Healthcare Partners and Delta Partners.

Genable is a bio-pharmaceutical company developing new gene medicines to treat "dominant" genetic diseases based on the pioneering work of Professor Jane Farrar, Dr Paul Kenna & Professor Peter Humphries of Trinity College Dublin. Genable's first gene medicine - GT038 - is for treatment of patients with a debilitating form of inherited blindness.

Storyful

Mason Hayes & Curran acted for Storyful on a significant investment by ACT Venture Capital, SOS Ventures and Ray Nolan, technology entrepreneur.

Storyful is a global online news service which filters information, analysis and opinion from social media platforms. It was founded by former RTE presenter, Mark Little.

TriMod Therapeutics

Mason Hayes & Curran acted for TriMod Therapeutics Limited on a €750,000 investment by Oyster Technology Investments Limited, Opsona Therapeutics Limited and Enterprise Ireland.

TriMod Therapeutics is a biotechnology company which is developing a therapeutic platform that enhances a cancer patient’s immune system in order to eradicate tumours. The founders of TriMod Therapeutics are Dr Jeremy Skillington (Opsona / Genetech) and Dr Kingston Mills (Opsona / Head of Immunology at TCD).